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Essentials
• Factor IX (FIX) dosing using body weight frequently results in under and overdosing during surgery.
• We aimed to establish a population pharmacokinetic (PK) model describing the perioperative FIX levels.
• Population PK parameter values for clearance and V1
were 284 mL h À1 70 kg À1 and 5450 mL70 kg À1 .
• Perioperative PK parameters differ from those during non-surgical prophylactic treatment.
Summary. Background: Hemophilia B is a bleeding disorder characterized by a deficiency of coagulation factor IX (FIX). In the perioperative setting, patients receive FIX concentrates to ensure hemostasis. Although FIX is usually dosed according to bodyweight, under-and overdosing occurs frequently during surgery. ; V2, 4800 mL70 kg
À1
; Q3, 1610 mL h À1 70 kg À1 ; V3, 2040 mL70 kg À1 . From 0.2 years, CL and V1 decreased 0.89% and 1.15% per year, respectively, until the age of 34 years. Patients receiving pdFIX exhibited a lower CL (11%) and V1 (17%) than patients receiving rFIX. Interpatient variability was successfully quantified and explained. Conclusions: The estimated perioperative PK parameters of both pdFIX and rFIX are different from those reported for prophylactic treatment. The developed model may be used to apply PK-guided dosing of FIX concentrates during surgery.
Introduction
Hemophilia B is a bleeding disorder characterized by a deficiency of coagulation factor IX (FIX). Severe and moderate patients have endogenous FIX levels less than 0.01 IU mL À1 and between 0.01 and 0.05 IU mL À1 , respectively [1, 2] . In this category of patients, plasmaderived FIX (pdFIX) or recombinant FIX (rFIX) standard half-life concentrates are usually administered prophylactically to prevent spontaneous joint and muscle bleedings [3, 4] and 'on-demand' when bleeding occurs in the surgical setting. In the prophylactic setting, FIX trough levels above 0.01 IU mL À1 are usually aimed for, as moderate patients have significantly fewer spontaneous bleeds [5] . In the perioperative setting, higher doses of FIX concentrates are administered to normalize FIX levels for 7-10 consecutive days post-surgery, with target trough levels from 1.00 to 0.30 IU mL À1 ensuring adequate hemostasis [6] .
Currently, prophylactic, 'on-demand' and perioperative dosing of FIX concentrates is performed according to bodyweight with frequent monitoring to ensure sufficient FIX levels. Despite weight-based dosing, considerable under-and overdosing in the surgical setting has been reported by Hazendonk et al. [7] . It was shown that 60% of hemophilia B patients have FIX levels below the target level range during the first 24 h directly after surgery. This lack of adequate FIX plasma levels confers a considerable potential risk of bleeding and should be avoided. Therefore, more optimal dosing strategies are warranted.
In the prophylactic setting, FIX doses can be tailored to an individual's need by pharmacokinetic (PK)-guided dosing using Bayesian analysis [8] . In this approach, observed individual FIX levels are combined with PK information assessed in the population in order to obtain estimates for individual PK parameters [9] . These individual parameter estimates can be used to calculate doses necessary to achieve and maintain desired target levels by PK-guided dosing, potentially preventing over-and under-dosing. This approach can be applied iteratively, because with every new blood sample the calculated dose can be adapted to alterations in the individual PK parameter estimates [10] . This technique may also be applied in the perioperative setting.
A prerequisite for applying Bayesian analysis to perioperative dosing of FIX is the availability of a population model that describes the PK of FIX in hemophilia B patients undergoing surgery. The population PK of pdFIX and rFIX is well documented [5, [11] [12] [13] . However, these models have all been constructed using data during nonsurgical dosing of FIX concentrates. In the perioperative setting, the PK of FIX may, however, be altered. In order to apply Bayesian dosing in the perioperative setting, a dedicated population model should be available.
This study was performed to describe the population PK of pdFIX and rFIX concentrates in hemophilia B patients during surgery and the days thereafter. It was investigated whether specific patient and surgical characteristics explain interpatient variability (IIV) in FIX exposure and whether the perioperative PK of FIX is similar to the prophylactic situation.
Methods

Patients and clinical data
An international multi-center observational cohort study was performed in which data were collected from 118 severe and moderate hemophilia B patients from five Hemophilia Treatment Centers in the Netherlands and five in the United Kingdom. Patients of all ages, who had undergone a minor or major elective surgical procedure between 1 January 2000 and 1 December 2015, were included [14] . Details of the study data have been reported previously [7] .
In summary, severe and moderate hemophilia B patients received replacement therapy during surgery with FIX concentrates according to national and/or hospital guidelines, while aiming for target FIX levels as prescribed. To ensure hemostasis during the surgical procedure, a pdFIX product ( 
Pharmacokinetic modeling
In population PK modeling, the PK is assessed in a cohort of patients rather than in an individual patient [15] . In population PK modeling, not only the average or median value of a PK parameter is of interest but also its inter-and intra-patient variability. Population PK parameters can be obtained by the standard two-stage method, in which individual PK parameters are calculated and, subsequently, summarized. A drawback of this method is that for each individual 10 or more serial samples should be available (rich sampling). In the clinical situation, this is often impossible or inconvenient to perform, especially in populations such as children or the elderly. An alternative is the population approach [16] , which allows the estimation of population PK parameters by analyzing data from all the patients simultaneously. The simultaneous analysis allows the use of sparsely and heterogeneously sampled data, which are frequently encountered in the clinical situation. In this study, sparsely and heterogeneously sampled data were used to construct the population PK model. Using the population-based approach, a structural PK model is established first. This model consists of a number of PK compartments, with PK parameters described in terms of clearance and volume of distribution. The structural model provides values for the typical (average) parameter and, importantly, several levels of variability. Differences in PK parameters between patients are quantified in terms of interpatient variability (IIV). Variability of a PK parameter within a patient may be quantified by estimation of inter-occasion variability (IOV). Furthermore, a population PK model contains residual unexplained variability, which is the variability of the differences between the predicted and the measured plasma levels. By combining observed individual FIX levels and population PK parameters, empirical Bayesian estimates of the individual PK parameters can be obtained. These empirical Bayesian estimates can be used in the covariate analysis (below).
In this study, nonlinear mixed-effects modeling was used to estimate the population PK parameters [17] . A detailed description of the methods used to construct the population PK model can be found in Data S1. For each patient, the (historically lowest) endogenous baseline level was subtracted from each observed FIX level. Furthermore, in some subjects, a preoperative FIX level was present that was higher than the measured endogenous baseline level and for which no prior dose information was known. In the modeling procedure, the preoperative level was accounted for by an arbitrary virtual dose of 8250 IU administered 5 days prior to the pre-dose FIX measurement. To account for inter-and intra-individual variability in the observed preoperative FIX levels, the typical bioavailability of this dose was estimated in combination with its IIV and IOV. For estimation of the IOV, an occasion was defined as a single surgical procedure.
After the structural model was established, it was evaluated whether patient and surgical characteristics (covariates) explained the variability (IIV, IOV and residual unexplained variability) in a covariate model. Because FIX levels were available for both children and adults, estimated PK parameters were normalized for a bodyweight of 70 kg using allometric scaling with the ¾ rule [18] . Bodyweight was, however, missing in 38 surgical procedures (14.9%) involving 18 patients (15.3%). Therefore, a piecewise linear model was developed to impute the missing values for bodyweight using age as a predictor. Covariate relationships were evaluated using graphical evaluation of plots of the empirical Bayesian estimates vs. the covariate value. Subsequently, covariates were implemented in the population model and their ability to explain the IIV, IOV or residual unexplained variability was tested by univariate analysis. The following covariates were evaluated: severity of hemophilia (severe vs. moderate), age, the use of tranexamic acid or heparin during surgery, the type of FIX concentrate (plasma derived or recombinant), the brand of product, treatment center, country of treatment, presence of hepatitis C, the use of prophylaxis before the surgical procedure, a history of neutralizing inhibitors, having a minor or major surgical procedure, blood group and the presence of an infection or a decrease in hemoglobin concentration during the surgical procedure. The final model, containing multiple covariates, was constructed by multivariate analysis using forward inclusion and backward deletion.
Model evaluation
The objective function value (OFV), which represents the ability of the model to describe the observed FIX levels, was used to discriminate between different models. When comparing nested models, the difference of the corresponding OFVs (dOFV) is known to be described by a chisquared distribution, in which the difference in the number of parameters between the evaluated models determines the degrees of freedom. Therefore, a dOFV bigger than 3.84, 5.99 or 7.81 indicates a significant difference of P < 0.05 with 1, 2 or 3 degrees of freedom, respectively. In the covariate analysis, covariates were selected in the forward inclusion and backward elimination procedure if dOFVs bigger than 3.84 (P < 0.05, d.f. = 1) and 6.63 (P < 0.01, d.f. = 1), respectively, were obtained.
To evaluate whether the measured FIX levels were adequately described by the developed population PK model, several criteria were used. The adequacy of the model was evaluated by inspection of precision of the estimated model parameters, creation of goodness-of-fit plots, evaluation of shrinkage of the IIV, IOV and residual unexplained variability, the condition number of the model and the creation of visual predictive checks [19, 20] . In the latter procedure, FIX levels were generated by Monte Carlo simulation (n = 1000) using the established population PK model and are, subsequently, compared to the actual measured FIX levels [21] . For the goodness-of-fit plots, the measured FIX levels were compared with the population predicted FIX levels using the typical values for the PK parameters and the individual FIX levels predicted on basis of the empirical Bayesian estimate. Moreover, several plots were evaluated depicting conditional weighted residuals (CWRES). CWRES are the weighted difference between the model-predicted and measured FIX levels [22] .
The stability and robustness of the final model were tested by a bootstrap analysis [23] . In this analysis, 1000 new datasets were created by randomly sampling from the data from all patients in the original dataset. Subsequently, the final model was re-estimated using the bootstrapped datasets. The median and 95% confidence interval of the obtained bootstrap parameters were compared with the estimated PK parameters of the final model.
Comparison with non-surgical FIX models
The final population model describing the PK of FIX in hemophilia B patients during surgery was compared with published population PK models derived from data of patients on prophylaxis [11] [12] [13] 24] . To evaluate whether the published prophylactic models were able to describe the perioperative FIX levels from this study, predictions of the perioperative FIX levels were calculated using the prophylactic population PK parameters. For each model, the difference between the population predictions and the measured FIX levels was summarized using the relative mean prediction error (rMPE). The latter was calculated using the following equation:
in which C pred are the population predictions and C FIX:C the measured FIX level for a total of n measurements. Furthermore, the terminal elimination half-life was calculated using the values from all population PK parameters.
Results
Patients
In total, 118 severe and moderate hemophilia B patients were included, undergoing 262 surgical procedures. Four occasions were excluded, as FIX levels were not measured. Because of the withdrawal of approval for IXinity Ò by the European Medicine Agency during data collection in June 2013, another three surgical procedures were also excluded from analysis [25] . As a result, data from 255 surgical procedures were used for PK analysis. Table 1 shows the general patient characteristics. Bodyweight was not recorded in 14.9% of all surgical procedures. Therefore, a piecewise linear model was developed, from which the missing values for bodyweight could be imputed using age (Data S1). Table S1 shows the parameter estimates for the piecewise linear model. The relationship between age and bodyweight is shown in Fig. 1 ; the blue line depicts the predictions from the model for all ages, which was used to impute values for the missing bodyweights.
Pharmacokinetic modeling
For constructing the structural model, a three-compartment model more adequately fitted the FIX levels than a two-compartment model (dOFV = 58.1, P < 0.001) (Figure S1 ). Table 2 summarizes the parameter estimates of the structural model. For all estimated PK parameters, the imprecision of the estimated value was lower than 20%. A proportional residual error model was most appropriate to fit the data, as compared with an additive or combined residual error model. In the structural model, IIV could be estimated for both CL and V1, as well as a correlation for the IIV between the two parameters. Moreover, shrinkage values for the IIV of CL and V1 were lower than 20%, indicating that there was sufficient information available for each patient to estimate the individual parameters reliably [26] . Although IIV should also be present for the other PK parameters (e.g. Q2, Q3, V2, V3), the available data did not support the estimation of these values. Pre-administration FIX levels (greater than endogenous baseline values) were present in 138 of the 255 evaluated surgical procedures and ranged from 0.01 to 0.67 IU mL À1 . Administration of a virtual dose of 8250 IU, 120 h before the start of the surgery, adequately approximated the pre-administration FIX levels and significantly improved the fit of the model; dOFV was À 495.5 (P < 0.001). To prevent the covariates influencing the estimation of the virtual dose, the IIV and IOV from the virtual dose were fixed to the values obtained for the structural model. Table 3 shows the dOFV for the selected covariate relations from the forward inclusion and backward elimination procedure. Age of the patient was included for CL and V1 as a piecewise linear model, which is a linear model with two slopes. The best fit was obtained when the first slope was estimated and the second was set to zero from an age of 34 years, which was the median, and higher. As a result, the bodyweight-normalized CL and V1 decreased 0.89% and 1.15% per year, respectively, until the age of 34 years. Moreover, IIV was reduced from 20.8% to 18.5% (10.1%) and from 24.6% to 18.7% (14.6%) for CL and V1 as a result of the introduction of age. In Fig. 2(A,B) , age vs. individual values for CL and V1, as obtained by Bayesian analysis using the final model, are shown. In these figures, the combined effect of bodyweight and age is observed, as CL and V1 increase with bodyweight and decrease with age up to 34 years. Patients receiving pdFIX concentrates exhibited a lower CL and V1 as compared with patients receiving rFIX concentrates; respective values were 11% and 17% lower for pdFIX. Moreover, V1 was 10% lower in patients with moderate hemophilia in comparison to patients with severe hemophilia. The parameters of the final model are summarized in Table 2 . All other covariate relations did not result in a significant dOFV.
Evaluation of the final model
The fit of the final model was evaluated by inspection of goodness-of-fit plots, as shown in Fig. 3(A-D) . Figure 3(A) shows the prediction of FIX levels, based on the population PK parameter values, adjusted for the covariate values. Both under-and overprediction are present because IIV is not taken into account for calculating the population predictions. Nevertheless, the population predictions are distributed randomly around the y = x axis, demonstrating the appropriateness of the model. Figure 3(C,D) shows plots of the conditional weighted residuals (CWRES) vs. predicted FIX level and time, respectively. CWRES values are distributed randomly around the line y = 0 (see also Figure S3 ). Most of the values are within the À 2 and + 2 SD range, which confirms the goodness-of-fit of the final model.
To evaluate the stability of the final model, a bootstrap analysis was performed. In this analysis, 1000 model estimations were performed, from which 98.3% were successful. Table 2 shows that the medians for the parameter estimates from the bootstrap analysis were similar to those from the final model, except for Q3. This deviation for Q3 is caused by the high imprecision of its estimation, as shown by the 95% CI for Q3 from the bootstrap analysis (667.2-5131.9 mL h À1 70 kg
À1
). For all other parameters of the final model, the CIs were small and corresponded to the relative standard errors from the parameter estimates of the final model. The evaluation of the final model comprised 1000 Monte Carlo simulations for each patient to construct a visual predictive check, as shown in Fig. 4 (and Figure S4) . The (grey) lines, depicting the 2.5th, 50th and 97.5th percentiles of the measured FIX levels, are predominantly within their corresponding 95% prediction OFV indicates objective function value, as calculated by minus two times the logarithm of the likelihood (À 2LL) of the model describing the data; dOFV, difference of the corresponding OFVs; CL, clearance; ND, not determined; No., number; V1, volume of distribution of the central compartment. *For these models, the coefficients for covariate age on both CL and V1 were estimated using a piecewise linear model. However, the slope for the ages above 33.6 years was fixed to 0. Therefore, the number of parameters only increases by 1. intervals, as presented by blue and red areas. As a result, the simulated data were similar to the measured data, confirming the adequacy of the final model.
Comparison with non-surgical models Table S2 summarizes population PK parameters of four models that have been published previously and were constructed using data obtained after non-surgical dosing. Higher values for the population PK parameter CL were found for the rFIX models as compared with the pdFIX models. Figure S2 shows the predicted FIX levels as obtained using the population PK parameter values analogous to Fig. 3(A) (without IIV). Figure S2 (A,B) was constructed using solely the pdFIX data from this study; concentrations were predicted using the population parameters of pdFIX model 1 and 2. Likewise, Figure S2 (C,D) was constructed using solely the rFIX data from this study in combination with population parameters from rFIX model 1 and 2. In each case, the nonsurgical models underpredicted the observed levels, as shown by the blue lines being above the black line y = x. The rMPE values, calculated for pdFIX model 1 and 2 and rFIX model 1 and 2, were À 7.2%, À 15.7%, À 40.7% and À 40.3%, respectively. Furthermore, the half-lives calculated for pdFIX and rFIX using the population parameter values for the final model from the present study were 51 and 49 h, respectively, whereas the terminal elimination half-lives for pdFIX model 1 and 2 and rFIX model 1 and 2 were: 28, 23, 20 and 20.3 h, respectively.
Discussion
In this study, the PK of pdFIX and rFIX were characterized in children and adults with severe and moderate hemophilia B undergoing a surgical procedure. Considerable interpatient variability was identified for clearance and central volume of distribution, which was partially explained by the patient's age, type of FIX product and the severity of hemophilia. Importantly, the perioperative PK parameter of FIX was different from that in the nonsurgical situation.
In population PK analysis, the variability within and between patients is quantified and, subsequently, explained using covariates such as age or bodyweight. When these variabilities are assessed adequately, a population PK model may be used for PK-guided dosing using Bayesian analysis. In contrast to dosing based on bodyweight, PK-guided dosing allows for individualization of doses while taking the individual's PKs into account. To apply Bayesian analysis clinically, an appropriate population PK model is essential. Moreover, Bayesian analysis using a population PK model, which does not describe the PKs of FIX adequately, may result in biased individual PK parameters and, hence, biased estimated doses. For FVIII, a dedicated population PK model for hemophilia A patients undergoing a surgical procedure was constructed in a similar fashion [27] . Therefore, a dedicated population PK model was constructed to describe the perioperative FIX levels. In this study, the observed presurgical FIX level was higher than the endogenous baseline value in 138 of 255 surgical procedures. These elevated presurgical FIX levels were taken into account by a virtual dose that was estimated using a typical value and both IIV and IOV. Thereby, each patient having a presurgical FIX level can have a different virtual dose for each surgical procedure. Inclusion of these presurgical FIX levels greatly improved the fit of the model. Therefore, exclusion of such presurgical FIX levels may lead to biased population PK parameter estimates.
In the present study, age partially explained the interindividual variability from CL and V1. In the final model, the best fit was obtained using a piecewise linear relation using two slopes with À 0.89% and À 1.15% for ages below 34 years for bodyweight-normalized CL and V1, respectively. Allometric scaling of CL using an exponential factor of 0.75 partly explains the increased clearance when a lower bodyweight is present. Nevertheless, additional variability was explained by taking age into account. Bj€ orkman et al. reported a similarly piecewise linear relationship between age and CL of rFIX when administered in a non-surgical situation [28, 29] . It was shown that clearance and (steady-state) volume of distribution decreased when age increased from 2 to 20 years. Above an age of 20 years, there was virtually no change in clearance or volume of distribution. Suzuki et al. explored a similar piecewise relationship of age with CL for the population PKs of rFIX as well [13] . However, a relationship between age and CL could not be identified when bodyweight was included in the model as well. Furthermore, in the covariate analysis, severity of hemophilia B was associated with V1. For a moderate hemophilia B patient, V1 was 10.5% lower as compared with a severely affected patient, which is in agreement with the findings from Ewenstein et al. [30] .
In previous studies, differences have been reported between PK parameters from pdFIX and rFIX products in the non-surgical situation [5, 30, 31] . The in vivo recovery for rFIX products was found to be on average 53% that of pdFIX products [5] . As in vivo recovery is inversely related to volume of distribution, V1 is lower for pdFIX products. Moreover, the clearance of rFIX products was found to be approximately twice as high as compared with pdFIX products [32] . In the present study, CL and V1 of pdFIX were 11.2% and 17.3% lower than their respective values for rFIX. These higher values for CL and V1 from rFIX are in accordance with results from previous studies. However, the difference between the types of products is smaller in the surgical situation than in the non-surgical situation.
In Figure S2 , each published non-surgical population PK model showed that the observed perioperative FIX levels were underpredicted. These differences were also demonstrated by simulations of the typical FIX level vs. time profiles for a patient receiving 100 IU kg À1 of pdFIX or rFIX using the available population PK models ( Figure S5 ). The calculated rMPEs and half-lives clearly demonstrate that the PK of FIX in the non-surgical setting is different from the surgical setting. 
kg
À1 . An explanation for this difference is unknown. Nevertheless, the currently published population PK models for prophylactic treatment with rFIX and pdFIX underpredict the perioperative FIX levels. Consequently, use of these models in the perioperative situation results in overdosing.
Conclusion
In the present study, a population PK model was established that adequately described the perioperative FIX levels obtained from hemophilia B patients undergoing a surgical procedure. As differences in the population PK parameters were found between the surgical and non-surgical setting, the dedicated population PK model constructed in this study may be applied for patient-tailored dosing in the perioperative period. However, application of a population PK model for clinical use should always be validated.
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